Navigation Links
Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkin's Lymphoma
Date:12/10/2007

SEATTLE, Dec. 10 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that Wyeth Pharmaceuticals has initiated a Phase I/II clinical trial of TRU-015, Trubion's lead Small Modular ImmunoPharmaceutical (SMIP(TM)) drug candidate, for the treatment of non-Hodgkin's lymphoma (NHL). The nonrandomized, open label, uncontrolled, single-group assignment clinical trial is designed to evaluate the safety and efficacy of TRU-015 in subjects with NHL. Trubion is co-developing TRU-015 and other CD20-directed therapies with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).

"We believe that TRU-015 may be a valuable tool in the treatment of NHL, and we are looking forward to working with Wyeth as this development program moves forward," said Peter Thompson, M.D., FACP, president, chief executive officer and chairman of Trubion.

TRU-015 Phase I/II Clinical Trial Protocol

The Phase I/II clinical trial is expected to enroll approximately 120 NHL subjects who have undergone two or more prior therapies and have relapsed or refractory disease. Efficacy will be evaluated according to disease response and progression status per the International Response Criteria for NHL. Participants will receive an escalating dose of four weekly infusions of TRU-015. Once a maximum tolerated dose is confirmed, or once a maximum dose to be studied is determined to be safe and well tolerated, an expanded cohort of subjects with relapsed follicular NHL will be evaluated for efficacy.

Trubion
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... -- CVS Health Corporation (NYSE: CVS ) will ... 2015, at 8:30 a.m. (EDT) with analysts and investors ... An audio webcast of the conference call will be ... CVS Health website for all interested parties. To access ... be archived and available on the web site for ...
(Date:4/17/2015)... SAN DIEGO , April 17, 2015 /PRNewswire/ ... molecular diagnostics, announced today that clinical data presented ... demonstrate that its urine-based Precision Cancer Monitoring ℠ ... detection and monitoring of EGFR T790M ... titled Detection of EGFR T790M Mutation in ...
(Date:4/17/2015)... 2015  Over the next five years, the marijuana industry ... ArcView predicting that 14 more states will legalize recreational marijuana ... market for legal cannabis grew 74 percent in 2014 to ... the market could grow more than fourfold to $11 billion ... stance on marijuana. Cannabiz Mobile Inc. (OTCBB: LGBI) ...
Breaking Medicine Technology:Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2
... Timothy Mastro,MD, FACP, DTM&H, who joins Family Health ... Research, will share information on promising,research into pre-exposure ... Conference in Mexico City., Dr. Mastro,s presentation, ... ongoing and upcoming clinical trials that,suggest oral doses ...
... Key Thought,Leaders Explore Critical Next Steps for AIDS Vaccine ... NEW YORK, July 28 The following was ... Today, AIDS vaccine research is at a pivotal ... to reach late-stage testing failed.,In the wake of this ...
Cached Medicine Technology:HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference 2AIDS Vaccines: Where Do We Go From Here? 2
(Date:4/19/2015)... (PRWEB) April 19, 2015 The American ... up with PROSHRED Security (“PROSHRED”) to host its second ... to shred their personal documents in order to raise ... prevention. , The June 6th event is being held ... – 2pm local time. The time will vary at ...
(Date:4/19/2015)... Houston, Texas (PRWEB) April 19, 2015 ... is pleased to announce the publication of white paper ... Online Affair . As online media provides a ... whole new niche market specifically targeting adulterous spouses ... which an affair becomes as easy as shopping online. ...
(Date:4/19/2015)... Hanover, MA (PRWEB) April 19, 2015 Family ... Bowling for Brains in Memory of Brad Baddeley ... renowned Brain Aneurysm Foundation. , Bowling for Brains is cheduled ... Bowling located 4700 Dudley Street in Lincoln, Nebraska. Participants may ... from 1:00 to 3:00pm. , The cost is only $4 ...
(Date:4/18/2015)... (PRWEB) April 19, 2015 For some people, ... proudly display for the rest of their lives, as they ... them and put in a great amount of thought on ... whim, they have outgrown them or simply want them removed ... people regret their tattoo, and in 2012-13 there was a ...
(Date:4/18/2015)... April 18, 2015 Compare-autoinsurance.org has released ... reliable auto insurance policy . , Clients ... car insurance quotes online is safe and reliable. An ... The quotes are displayed on a single web page, ... , It is now possible to compare online ...
Breaking Medicine News(10 mins):Health News:2015 Annual Nationwide "Shred Cancer" Shredding Event 2Health News:McCann Investigations Publishes White Paper Married, but Dating: The Rise of the Married Online Affair 2Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 2Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 3Health News:Dennis Dass, M.D. is Shattering the Past While Revealing the Future 2Health News:A Guide For Avoiding Online Auto Insurance Scams! 2
... Now Offers Industry,s Only Kiosk-Based Multiple Simultaneous Sessions Capability ... ... April 7, 2009 -- Passlogix ®, Inc., today announced ... and shared workstations with the newest edition of v-GO ...
... Mullican and Janynne Stahl have launched Totally Texty, a new hair care ... and tweens. An informational website designed around common texting words popular with ... head smell problem and fill a gap in the teen hair care ... ...
... wise to trust the female nose when it comes to body ... is more difficult to mask underarm odor when women are doing ... block a woman,s awareness of body odor. In contrast, it seems ... Charles J. Wysocki, PhD, a behavioral neuroscientist at Monell. ...
... A group of Hollywood,s new moms, ... in a new public service announcement (PSA) to show ... walking event that helps moms have full-term pregnancies and ... )Volunteer moms include - Standing: ...
... Association Scientific StatementDALLAS, April 6 /PRNewswire-USNewswire/ ... procedures to treat brain blood vessel diseases has ... with advances in the field of catheter-based interventions. ... providing recommendations for their use based on the ...
... 6 ULURU Inc. (NYSE Amex: ULU ... to publish by the Takeover Panel in the United Kingdom. ... offer or not, the Form 8-K filing made by ULURU on ... the UK Takeover Code (the "Code"). For more information, please ...
Cached Medicine News:Health News:Passlogix Introduces Industry's Fastest Sign-On to Kiosks with New Enhancements to v-GO Session Manager 2Health News:Passlogix Introduces Industry's Fastest Sign-On to Kiosks with New Enhancements to v-GO Session Manager 3Health News:Passlogix Introduces Industry's Fastest Sign-On to Kiosks with New Enhancements to v-GO Session Manager 4Health News:New Hair Product Line Addresses Common Scalp Conditions of Teens and Tweens 2Health News:New Hair Product Line Addresses Common Scalp Conditions of Teens and Tweens 3Health News:A woman's nose knows body odor 2Health News:Hollywood Moms Team Up For March For Babies 2Health News:American Heart Association Statement Gives Guidance on Minimally Invasive Procedures to Treat Diseased Brain Vessels 2Health News:ULURU Inc. ('ULURU') Dealing Disclosure Requirements 2Health News:ULURU Inc. ('ULURU') Dealing Disclosure Requirements 3
The BUN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of urea nitrogen in serum, plasma and urine....
The XTRI method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of triglycerides in serum and plasma....
CK-MB Control...
For the quantitative in vitro determination of CK-MB in serum and plasma...
Medicine Products: